Sarah Waheed - Concepedia

Author

Sarah Waheed

University of Arkansas for Medical Sciences

Also Known As

S Waheed, S. Waheed, SAPNA WAHEED, Saquib Waheed, Sarah Waheed, Shahbaa Waheed, Waheed, Sarah

171

Publications

3.2K

Citations

H-Index

Concepts

All Affiliations

University of Arkansas for Medical Sciences Cancer Research And Biostatistics University of Chicago

About

Sarah Waheed is an author at University of Arkansas for Medical Sciences specializing in medicine, radiation oncology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	591
2	Health Sciences	5	5	489
3	Immunology	4	4	369
4	Cell Biology	2	2	220
5	Cellular Therapies	1	1	179

Sarah Waheed

Publications

2.9K

Citations

H-Index

Page 1

	Year	Citations
Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents Saad Z. Usmani, Christoph Heuck, Alyson E. Mitchell, Haematologica	2012	378
Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities Bart Barlogie, Mauricio Pineda‐Roman, Frits van Rhee, Blood	2008	227
Superior results of Total Therapy 3 (2003-33) in gene expression profiling–defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance Bijay Nair, Frits van Rhee, John D. Shaughnessy, Blood	2010	200
Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3 Saad Z. Usmani, Alan Mitchell, Sarah Waheed, Blood	2013	200
High-risk myeloma is associated with global elevation of miRNAs and overexpression of <i>EIF2C2/AGO2</i> Yiming Zhou, Lijuan Chen, Bart Barlogie, Proceedings of the National Academy of Sciences	2010	197
Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120) Madhav V. Dhodapkar, Rachael Sexton, Sarah Waheed, Blood	2013	196
Ex Vivo–expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo in High-risk Relapsed Multiple Myeloma Patients Susann Szmania, Natalia Lapteva, Tarun K. Garg, Journal of Immunotherapy Cell TherapyImmunologyImmunoeditingCell Replacement TherapyImmunotherapeutics	2014	179
Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3 John D. Shaughnessy, Pingping Qu, Saad Z. Usmani, Blood	2011	175
Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma James E. McDonald, Marcus M. Kessler, Michael W. Gardner, Clinical Cancer Research	2016	122
Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured? Saad Z. Usmani, John Crowley, Antje Hoering, Leukemia Hematological MalignancyOncologyHematologyClinical TrialsOutcomes Research	2012	113

Page 1